WHO Working On ‘Evolved’ Model For COVID-19 Licensing Platform
With companies still reluctant to share their IP and knowledge via the C-TAP platform, stakeholders will be offered the chance to comment on a proposed new model that is expected to cover drugs for other high-priority diseases.
You may also be interested in...
Coronavirus Notebook: EMA OKs Updated Cominarty Vaccine, UK Brings Forward Vaccination Campaign Amid Spread Of BA.2.86 Strain
The World Health Organization’s C-TAP has signed new COVID-19 vaccine licensing deals with Medigen Vaccine Biologics of Taiwan and a Spanish research body, while the WHO and UNICEF say overall immunization rates are rebounding after the pandemic backslide, but not in all countries equally.
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.
Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.